2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.

Slides:



Advertisements
Similar presentations
Effect of intensification of long-term highly active antiretroviral therapy (HAART) with raltegravir on proviral HIV-1 DNA in blood and gut associated.
Advertisements

2014 “Towards an HIV Cure” symposium Melbourne Genetically Characterizing the Role of Cell Proliferation in Maintaining Persistent HIV during Effective.
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir
CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):
Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.
HIV Research Design. HYPOTHESIS My hypothesis states that the protein kinase C activator, Prostratin from the Samoan mamala tree can treat HIV with its.
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Track A Report Guido Poli Vita-Salute San Raffaele University & Scientific Institute, Milano, Italy XVIII International AIDS Conference, Vienna, 2010.
Main questions on HIV persistence and on obstacles to HIV eradication Jean-Pierre Routy M.D. McGill University Montreal Toward an HIV cure: Insight into.
HIV 101 Review Evaluation Center for HIV and Oral Health Boston University School of Public Health Health & Disability Working Group.
Pediatric HIV “Cure” HIV Cure Research Training Curriculum
Instructions To use this template: –for each slide write the correct answer on the orange bar first –choose which option (A,B,C or D) and make sure you.
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
Marian Kerbleski, RN UCSF AIDS Division San Francisco General Hospital.
Alternative RNA splicing in latently infected T cells generates chimeric cellular:HIV mRNAs with the potential to generate Tat and reactivate infection.
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
2014 “Towards an HIV Cure” symposium Melbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-nai ̈ ve individuals.
Current HIV basic science research topics. Toddler "Functionally Cured" of HIV Infection- “the Mississippi Baby” First well-documented case of an HIV.
Measuring the latent HIV Reservoir
Strategies for Targeting and Eradicating the HIV Reservoir
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Blocviroc – an innovative treatment for HIV/AIDS Steve English Development Head, Antivirals.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
AIDS Cure Research- Moving Into the Clinic Matt Sharp Long-term Survivor and AIDS Cure Activist San Francisco.
Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.
Future directions in HIV basic science research The hunt for a cure.
Latent infection and cellular reservoirs
2014 “Towards an HIV Cure” symposium Melbourne The Role of a Public-Private Partnership in HIV Cure Mike McCune, MD, PhD University of California, San.
HIV, CD4, and More Karen Hutcherson Jenn Mann Elizabeth McCauley Michael Powers Courtney Wilson.
Plate 87 Acquired Immune Deficiency Syndrome (AIDS)
Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.
Recurrent Respiratory Papillomatosis (RRP): Basic Science to Clinical Studies Mark J. Shikowitz, MD Bettie M. Steinberg, PhD Long Island Jewish Medical.
Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.
HIV Cellular Pathogenesis III
Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.
Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.
11 NAPWA Symposium 6 th IAS Meeting An HIV-based Lentiviral Vector Vaccine Achieves Functional Cure Post-challenge in a Subset of Vaccinated Macaques Dr.
Are we most likely to cure HIV with gene therapy? Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.
What is gene therapy? Do now: In your own words,
HIV: Science, Sex and Society. Lecture 2. Strategies for the cure of HIV-1. Mario Stevenson, Ph.D Department of Medicine.
Title Box. “Towards an HIV Cure”: Presentation Outline -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART.
HBV (chronic) HIV ~400 million chronically infected
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,
Immune reconstitution Anjie Zhen, PhD
No New Virus Produced No New Virus Produced New Virus Produced New Virus Produced Ligand Inserted Into Exosite Ligand Inserted Into Exosite HIV Protease.
Page 1 This is page one. I’m talking about it now….
Moiz Bakhiet, MD, PhD, Professor and Chairman
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
Walter + Eliza Hall Institute of Medical Research
Rapporteur Report – Track A Basic and Translational Sciences
State of HIV Cure Research
HIV Cure: Current Status and Future Perspectives
Feedback meeting September 2017
Broadening Eligibility Criteria to Make Clinical Trials More Representative Joint Recommendations of the American Society of Clinical Oncology and Friends.
HEATHER Feedback Meeting
Human Health and Disease
The block-and-lock approach
Why we should ‘shock and kill’
Engineering T Cells to Functionally Cure HIV-1 Infection
O. Turriziani, M. Andreoni, G. Antonelli 
Aim What happens when a bacteria or virus mutates?
Double Trouble: HIV Latency and CTL Escape
Immunologic strategies for HIV-1 remission and eradication
Presentation transcript:

2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of AIDS, NIH

THE 100 Million “Today I’m pleased to announce a new initiative at the National Institutes of Health to advance research into an HIV cure. We’re going to redirect $100 million into this project to develop a new generation of therapies. Because the United States should be at the forefront of new discoveries into how to put HIV into long-term remission without requiring lifelong therapies -- or, better yet, eliminate it completely.” President Obama World AIDS Day Dec 3, 2013

Why so much talk about “CURE” now?

Walker, range of early treated patients “time to rebound” Chun patient Boston patients Rebound Following Discontinuation of Therapy (modified from Davey)

Residual Virus Latently-infected cells cells? Other cellular compartments? Protected anatomical sites such as gut, brain, lymph nodes?

Homeostasis of Naïve and Memory CD4 T Cells

Establishment and Maintenance of a Latent Reservoir

Long-Lived Resting Memory CD4+T Cells Uninfected Resting Memory CD4+T cell Infected Resting Memory CD4+T cell Relative frequency1,000,0001 Molecules HIV protein00 Molecules HIV RNA00 Base pairs DNA6 x x 10 9 Survival of cell (and progeny)decades

NIH Plans for the Future Basic Research Translational Research Pilot Clinical Studies Phase I-IV Clinical Trials

Cure Web Page

We face complex and difficult challenges We are learning (even from our disappointments) We (the NIH) are working very hard to push for a deeper understanding of what contributes to persistence and to find new strategies to eliminate all forms of HIV in infected people. We face complex and difficult challenges We are learning (even from our disappointments) We (the NIH) are working very hard to push for a deeper understanding of what contributes to persistence and to find new strategies to eliminate all forms of HIV in infected people. Summary